A Guide to Diagnosis and Follow-up of Myelodysplastic Syndrome [Utilization Spotlight]
Since 2012, we have been publishing a Utilization Spotlight in every issue of the Communiqué. Each Spotlight offers a quick view of utilization management best practices in action. This Spotlight is from March 2016.
Overview
Myelodysplastic syndromes (MDS) are malignant hematopoietic stem cell disorders that occur primarily in the older adult population and have a yearly incidence of 30 in 100,000 in persons 70 years and older. The eventual clinical outcome for patients with MDS relates to either bone marrow failure or leukemic transformations.
Situation
Myelodysplastic syndromes (MDS) are malignant hematopoietic stem cell disorders that occur primarily in the older adult population and have a yearly incidence of 30 in 100,000 in persons 70 years and older. These disorders are typically associated with a hypercellular bone marrow and low peripheral blood counts, and with significant morbidity and mortality. The eventual clinical outcome for patients with MDS relates to either bone marrow failure or leukemic transformations.
Analysis
Conventional chromosome analysis is the gold standard for identification of the common, recurrent chromosome abnormalities in MDS. Cytogenetic studies can provide confirmatory evidence of clonality in MDS and can be used to provide clinical prognostic or diagnostic information.
Mayo Medical Laboratories Testing
Visit MayoMedicalLaboratories.com to view Mayo Medical Laboratories’ complete MDS test offerings.
- MYEFL / Myelodysplastic Syndrome by Flow Cytometry, Bone Marrow
- CHRBM / Chromosome Analysis, Hematologic Disorders, Bone Marrow
- NGSHM / OncoHeme Next Generation Sequencing (NGS), Hematologic Neoplasms
Additional Resources